Lopinavir
Highest phase reached
Approved
Drug type
Small molecule
First approval year
2000
- First approval year
- 2000
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Small molecule
- Drug name
- Lopinavir
- Molecular weight
- 628.81
- Structure (SMILES)
- Cc1cccc(C)c1OCC(=O)N[C@@H](Cc1ccccc1)[C@@H](O)C[C@H](Cc1ccccc1)NC(=O)[C@H](C(C)C)N1CCCNC1=O
- lopinavir component of kaletra
- Lopinavir component of kaletra
- (1S-(1R*(R*),3R*,4R*))-N-(4-(((2,6-DIMETHYLPHENOXY)ACETYL)AMINO)-3-HYDROXY-5-PHENYL-1-(PHENYLMETHYL)PENTYL)TETRAHYDRO-.ALPHA.-(1-METHYLETHYL)-2-OXO-1(2H)-PYRIMIDINEACETAMIDE
- (αS)-Tetrahydro-N-[(αS)-α-[(2S,3S)-2-hydroxy-4-phenyl-3-[2-(2,6-xylyloxy)acetamido]butyl]phenethyl]-α-isopropyl-2-oxo-1(2H)-pyrimidineacetamide
- 1s 1r r 3r 4r n 4 2 6 dimethylphenoxy acetyl amino 3 hydroxy 5 phenyl 1 phenylmethyl pentyl tetrahydro alpha 1 methylethyl 2 oxo 1 2h pyrimidineacetamide
- a 157378 0
- A-157378-0
- A-157378.0
- abt 378
- ABT-378
- aluviran
- Aluviran
- etravirine lopinavir ritonavir
- kaletra component lopinavir
- KALETRA COMPONENT LOPINAVIR
- koletra
- Koletra
- lopinavir
- Lopinavir
- LOPINAVIR [EMA EPAR]
- LOPINAVIR [EP MONOGRAPH]
- lopinavir [INN]
- LOPINAVIR [JAN]
- LOPINAVIR [MART.]
- LOPINAVIR [MI]
- LOPINAVIR [ORANGE BOOK]
- LOPINAVIR [USAN]
And 28 more, listed on the interactive page.
- CAS registry numbers
- 192725-17-0
- ChEMBL ID
- CHEMBL729
- InChIKey
- KJHKTHWMRKYKJE-SUGCFTRWSA-N
- PubChem compound IDs
- 92727
- RxNorm IDs (RxCUI)
- 195088
- FDA ingredient codes (UNII)
- 2494G1JF75
- Applicant
- ABBVIE
- Approval date
- 15 Sept 2000
- Application number
- NDA021251
- First in class
- No
- Orphan designation
- No
- Availability
- Prescription only
- Pharmacology name
- lopinavir
- Type
- Synthetic organic
- Drug name stem
- -vir
- Approval recorded by Guide to Pharmacology
- Yes
Administration routes
- Oral
Mechanisms of action
- Mechanism
- Human immunodeficiency virus type 1 protease inhibitor
- Action type
- Inhibitor
- Target
- Human immunodeficiency virus type 1 protease
- Protein identifier
- Q72874
Open Targets mechanisms
- Mechanism
- Human immunodeficiency virus type 1 protease inhibitor
- Action type
- Inhibitor
- Target
- Human immunodeficiency virus type 1 protease
DrugCentral mechanisms
- Action type
- Inhibitor
- Gene symbol
- pol
- Protein identifier
- Q72874
- Organism
- Human immunodeficiency virus 1
- Condition
- HIV Infections
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000180
- Subject identifier
- D015658
- Condition
- Infections
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000544
- Subject identifier
- D007239
- Condition
- Sarcoma, Kaposi
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000558
- Subject identifier
- D012514
- Condition
- Severe Acute Respiratory Syndrome
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000694
- Subject identifier
- D045169
- Condition
- HIV Infections
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000764
- Subject identifier
- D015658
- Condition
- Acquired Immunodeficiency Syndrome
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000765
- Subject identifier
- D000163
- Condition
- Insulin Resistance
- Highest recorded phase
- 1
- Condition identifier
- EFO:0002614
- Subject identifier
- D007333
- Condition
- Pregnancy
- Highest recorded phase
- 2
- Condition identifier
- EFO:0002950
- Subject identifier
- D011247
- Condition
- Hepatitis C
- Highest recorded phase
- 1
- Condition identifier
- EFO:0003047
- Subject identifier
- D006526
- Condition
- Pneumonia
- Highest recorded phase
- 3
- Condition identifier
- EFO:0003106
- Subject identifier
- D011014
- Condition
- Anus Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- EFO:0003835
- Subject identifier
- D001005
- Condition
- Coronavirus Infections
- Highest recorded phase
- 3
- Condition identifier
- EFO:0007224
- Subject identifier
- D018352
- Condition
- Influenza, Human
- Highest recorded phase
- 3
- Condition identifier
- EFO:0007328
- Subject identifier
- D007251
- Condition
- Respiratory Distress Syndrome
- Highest recorded phase
- 1
- Condition identifier
- EFO:1000637
- Subject identifier
- D012128
- Condition
- Tuberculosis
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0018076
- Subject identifier
- D014376
- Condition
- Severe Acute Respiratory Syndrome
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0100096
- Subject identifier
- D045169
- Condition
- Coronavirus Infections
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0100116
- Subject identifier
- D018352
- Condition identifier
- EFO_0000180
- Condition identifier
- EFO_0000180
- Highest recorded phase
- 4
- Condition identifier
- EFO_0000558
- Condition identifier
- EFO_0000694
- Condition identifier
- EFO_0000764
- Condition identifier
- EFO_0000765
- Highest recorded phase
- 3
- Condition identifier
- EFO_0002950
- Highest recorded phase
- 2
- Condition identifier
- EFO_0003835
- Highest recorded phase
- 1
- Condition identifier
- EFO_0007224
- Highest recorded phase
- 3
- Condition identifier
- HP_0002783
- Highest recorded phase
- 2
- Condition identifier
- HP_0100578
- Condition identifier
- MONDO_0003046
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005055
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005091
- Condition identifier
- MONDO_0005109
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0005136
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005231
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005344
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005347
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005354
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005388
- Condition identifier
- MONDO_0005812
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0006502
- Condition identifier
- MONDO_0008315
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0012268
- Highest recorded phase
- 3
And 7 more, listed on the interactive page.
- Event
- abortion induced
- Reports
- 265
- Reporting signal score
- 503.131
- Event
- abortion spontaneous
- Reports
- 686
- Reporting signal score
- 1,080.44
- Event
- congenital anomaly
- Reports
- 116
- Reporting signal score
- 208.791
- Event
- cushing's syndrome
- Reports
- 262
- Reporting signal score
- 715.767
- Event
- depression
- Reports
- 234
- Reporting signal score
- 148.959
- Event
- diplopia
- Reports
- 125
- Reporting signal score
- 216.644
- Event
- drug interaction
- Reports
- 1,223
- Reporting signal score
- 1,086.57
- Event
- drug resistance
- Reports
- 397
- Reporting signal score
- 609.681
- Event
- eyelid ptosis
- Reports
- 143
- Reporting signal score
- 216.389
- Event
- fanconi syndrome
- Reports
- 82
- Reporting signal score
- 208.767
- Event
- foetal death
- Reports
- 111
- Reporting signal score
- 234.349
- Event
- hyperbilirubinaemia
- Reports
- 259
- Reporting signal score
- 495.446
- Event
- hypertriglyceridaemia
- Reports
- 183
- Reporting signal score
- 361.067
- Event
- immune reconstitution inflammatory syndrome
- Reports
- 226
- Reporting signal score
- 506.434
- Event
- immune reconstitution syndrome
- Reports
- 145
- Reporting signal score
- 476.949
- Event
- injection site pain
- Reports
- 1
- Reporting signal score
- 219.607
- Event
- kaposi's sarcoma
- Reports
- 54
- Reporting signal score
- 135.474
- Event
- lipodystrophy acquired
- Reports
- 375
- Reporting signal score
- 1,390.61
- Event
- live birth
- Reports
- 205
- Reporting signal score
- 489.652
- Event
- low birth weight baby
- Reports
- 179
- Reporting signal score
- 320.521
- Event
- mitochondrial toxicity
- Reports
- 147
- Reporting signal score
- 562.335
- Event
- pain
- Reports
- 78
- Reporting signal score
- 216.266
- Event
- polydactyly
- Reports
- 86
- Reporting signal score
- 237.797
- Event
- premature baby
- Reports
- 629
- Reporting signal score
- 1,103.86
- Event
- premature delivery
- Reports
- 300
- Reporting signal score
- 502.814
And 9 more, listed on the interactive page.
- NCT00004578
- NCT00004580
- NCT00004581
- NCT00004582
- NCT00004583
- NCT00006144
- NCT00017992
- NCT00025727
- NCT00027339
- NCT00028301
- NCT00035932
- NCT00036452
- NCT00038220
- NCT00038480
- NCT00038636
- NCT00039741
- NCT00042289
- NCT00043953
- NCT00043966
- NCT00046033
- NCT00050895
- NCT00052117
- NCT00056641
- NCT00074581
- NCT00075907
And 172 more, listed on the interactive page.
- Dose
- 800 mg/200 mg
- Route
- Oral
- How often
- Once daily or twice daily
- Swallowed whole and not chewed, broken, or crushed
- Taken with or without food
- Hydrogen bond acceptors
- 5
- Hydrogen bond donors
- 4
- Polar surface area
- 120
- Calculated partition coefficient (ALogP)
- 4.33
- Calculated partition coefficient (XLogP)
- 5.9
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 1
- Rotatable bonds
- 15
- Heavy atoms
- 46
- Molecular formula
- C37H48N4O5
- Monoisotopic mass
- 628.36247064
- Natural product
- Yes
- 0074-3008
- 0074-3956
- 0074-4014
- 31722-556
- 31722-603
- 33342-163
- 33342-164
- 42385-933
- 42385-934
- Recorded assays
- 2,548
- Active assays
- 512
- Confirmatory
- Other
- Screening
- Summary
- HIV Protease Inhibitors
- Cytochrome P-450 CYP3A Inhibitors
These details could not be displayed.
Related records
Trials (239)
- "OK 2004 Study" (Only Kaletra 2004 Study): Study to Evaluate Suspending Nucleosides From Triple-Drug Therapy in HIV Subjects
- A Bioavailability Study of Rifabutin and Lopinavir/Ritonavir in Healthy Adult Subjects
- A Comparison of Two Anti-HIV Drug Regimens for Youth Who Have Failed Prior Therapy
- A Multi-centre, Double-blinded, Randomized, Placebo-controlled Trial on the Efficacy and Safety of Lopinavir / Ritonavir Plus Ribavirin in the Treatment of Severe Acute Respiratory Syndrome
- A Multicentre Trial of Second-line Antiretroviral Treatment Strategies in African Adults Using Atazanavir or Lopinavir/Ritonavir
- A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
- A Phase II/III Trial of Lopinavir/Ritonavir Dosed According to the WHO Pediatric Weight Band Dosing Guidelines
- A Phase III Study Comparing Two Different Anti-HIV Drug Combinations in HIV-Positive Patients Without Previous Anti-HIV Drug Therapy
- A Phase IIIb Study Comparing Two Boosted Protease Inhibitor-based HAART Regimens in HIV-infected Patients Experiencing Their First Virologic Failure While Receiving an NNRTI-containing HAART Regimen
- A PK and Salvage Study for Children With HIV-infection
- A Prospective/Retrospective,Randomized Controlled Clinical Study of Antiviral Therapy in the 2019-nCoV Pneumonia
- A Simplified Kaletra® (Lopinavir/Ritonavir)-Based Therapy Versus a Sustiva® (Efavirenz)-Based Standard of Care in Previously Non-Treated HIV-Infected Subjects
- A Study Exploring an Induction-Maintenance Kaletra-Based Therapy Versus a Sustiva-Based Regimen in Previously Non-Treated, HIV-1/HCV Co-Infected Subjects
- A Study of ABT-378/Ritonavir Combination in HIV-Infected Patients Who Have Taken Protease Inhibitors
- A Study of Combination Therapies to Treat COVID-19 Infection
- A Study of HIV-Disease Development in Aging
- A Study of the Preliminary Efficacy of DARE-HPV to Treat High-risk Persistent Human Papillomavirus (hrHPV)
- A Study of Two Different Doses of ABT-378/Ritonavir in HIV-Infected Patients Who Have Taken Protease Inhibitors and Non-Nucleoside Reverse Transcriptase Inhibitors
- A Study on Antiretroviral Therapy (ART) Naïve Patients On Different Regimens to Treat Hiv (NORTHIV)
- A Study to Compare Anti-HIV Drugs Given Twice a Day or Once a Day, With or Without Direct Observation
Approved for (1)
In development for (11)
- Acute respiratory distress syndrome Phase 1
- AIDS Phase 3
- Anus neoplasm Phase 1
- COVID-19 Phase 3
- Hepatitis C virus infection Phase 1
- Influenza Phase 3
- Kaposi's sarcoma Phase 2
- Middle East respiratory syndrome Phase 3
- Pneumonia Phase 3
- Severe acute respiratory syndrome Phase 3
- Tuberculosis Phase 1